Cargando…
Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and m...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890305/ https://www.ncbi.nlm.nih.gov/pubmed/33613752 http://dx.doi.org/10.7150/jca.50733 |
_version_ | 1783652487503282176 |
---|---|
author | Wang, Wenjie Xie, Hongyu Xia, Bairong Zhang, Liuchao Hou, Yan Li, Kang |
author_facet | Wang, Wenjie Xie, Hongyu Xia, Bairong Zhang, Liuchao Hou, Yan Li, Kang |
author_sort | Wang, Wenjie |
collection | PubMed |
description | Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and matched with 17 late stage, 23 benign ovarian tumor (BOT) and 24 uterine fibroid (UF) patients were utilized to perform plasma proteomics analysis using isobaric tag for relative and absolute quantitation (iTRAQ) method to identify differential diagnostic proteins of ovarian cancer patients. A validation set of 9 early stage, 11 late stage, 17 BOT and 16 UF collected by an independent cohort of samples with the same matching principles was examined to confirm the expressed levels of differential expression proteins by ELISA analysis. Results: CRP and ARHGEF 11 were identified as potential diagnostic biomarkers of ovarian cancer. Results of area under the curve (AUC) analysis suggested that combination of diagnostic proteins and CA125 achieved a much higher diagnostic accuracy compared with CA125 alone (AUC values: 0.98 versus 0.80), especially improved the specificity (0.97 versus 0.77). In addition, elevated plasma CRP levels were associated with increased risk of ovarian cancer. Conclusions: Current study found that plasma protein CRP was an indicator for monitoring the progression of ovarian cancer. Combination of plasma protein biomarkers with CA125 could be utilized to early diagnose of ovarian cancer patients. |
format | Online Article Text |
id | pubmed-7890305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-78903052021-02-18 Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics Wang, Wenjie Xie, Hongyu Xia, Bairong Zhang, Liuchao Hou, Yan Li, Kang J Cancer Research Paper Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and matched with 17 late stage, 23 benign ovarian tumor (BOT) and 24 uterine fibroid (UF) patients were utilized to perform plasma proteomics analysis using isobaric tag for relative and absolute quantitation (iTRAQ) method to identify differential diagnostic proteins of ovarian cancer patients. A validation set of 9 early stage, 11 late stage, 17 BOT and 16 UF collected by an independent cohort of samples with the same matching principles was examined to confirm the expressed levels of differential expression proteins by ELISA analysis. Results: CRP and ARHGEF 11 were identified as potential diagnostic biomarkers of ovarian cancer. Results of area under the curve (AUC) analysis suggested that combination of diagnostic proteins and CA125 achieved a much higher diagnostic accuracy compared with CA125 alone (AUC values: 0.98 versus 0.80), especially improved the specificity (0.97 versus 0.77). In addition, elevated plasma CRP levels were associated with increased risk of ovarian cancer. Conclusions: Current study found that plasma protein CRP was an indicator for monitoring the progression of ovarian cancer. Combination of plasma protein biomarkers with CA125 could be utilized to early diagnose of ovarian cancer patients. Ivyspring International Publisher 2021-01-15 /pmc/articles/PMC7890305/ /pubmed/33613752 http://dx.doi.org/10.7150/jca.50733 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wang, Wenjie Xie, Hongyu Xia, Bairong Zhang, Liuchao Hou, Yan Li, Kang Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics |
title | Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics |
title_full | Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics |
title_fullStr | Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics |
title_full_unstemmed | Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics |
title_short | Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics |
title_sort | identifying potential markers for monitoring progression to ovarian cancer using plasma label-free proteomics |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890305/ https://www.ncbi.nlm.nih.gov/pubmed/33613752 http://dx.doi.org/10.7150/jca.50733 |
work_keys_str_mv | AT wangwenjie identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics AT xiehongyu identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics AT xiabairong identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics AT zhangliuchao identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics AT houyan identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics AT likang identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics |